top of page


Retatrutide vs Semaglutide vs Tirzepatide: Which Is Better for Weight Loss in 2026?
A Quick Note Before You Begin In the span of just a few years, the medical weight loss landscape has been completely rewritten by a new class of medications. Semaglutide reset expectations in 2021. Tirzepatide pushed them further in 2022 and 2023. By late 2026, a third contender is reshaping the conversation again: retatrutide, a triple-agonist molecule with the most impressive early clinical data of any weight management medication to date. For patients considering medical w

Jan Medical Group
Oct 219 min read


Why Physician Supervision Matters When Using Tirzepatide or Semaglutide for Weight Loss
GLP-1 receptor agonists have changed the conversation around weight management more dramatically than any class of medication in decades. Tirzepatide and semaglutide, the active compounds behind Mounjaro, Zepbound, Ozempic, and Wegovy, produce weight loss outcomes once achievable only through bariatric surgery. Clinical trials have shown total body weight reductions of 15 to 22 percent, and for millions of people living with obesity or metabolic disease, that is genuinely lif

Jan Medical Group
Aug 89 min read
bottom of page
